KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Jazz Pharmaceuticals (JAZZ) over the last 17 years, with Q3 2025 value amounting to $1.1 billion.

  • Jazz Pharmaceuticals' Operating Expenses rose 3445.56% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 billion, marking a year-over-year increase of 1057.75%. This contributed to the annual value of $3.4 billion for FY2024, which is 297.01% up from last year.
  • Jazz Pharmaceuticals' Operating Expenses amounted to $1.1 billion in Q3 2025, which was up 3445.56% from $1.7 billion recorded in Q2 2025.
  • In the past 5 years, Jazz Pharmaceuticals' Operating Expenses registered a high of $1.7 billion during Q2 2025, and its lowest value of $445.5 million during Q1 2021.
  • Moreover, its 5-year median value for Operating Expenses was $830.1 million (2024), whereas its average is $892.1 million.
  • The largest annual percentage gain for Jazz Pharmaceuticals' Operating Expenses in the last 5 years was 12546.76% (2021), contrasted with its biggest fall of 3850.61% (2021).
  • Over the past 5 years, Jazz Pharmaceuticals' Operating Expenses (Quarter) stood at $847.4 million in 2021, then skyrocketed by 45.81% to $1.2 billion in 2022, then fell by 28.01% to $889.4 million in 2023, then grew by 0.9% to $897.4 million in 2024, then grew by 19.08% to $1.1 billion in 2025.
  • Its Operating Expenses stands at $1.1 billion for Q3 2025, versus $1.7 billion for Q2 2025 and $897.4 million for Q4 2024.